Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,205,145.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $547.91, for a total transaction of $5,205,145.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $22,197,477.83. The trade was a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Price Performance

United Therapeutics stock opened at $547.69 on Friday. The company’s 50 day simple moving average is $568.06 and its 200 day simple moving average is $518.61. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The firm has a market capitalization of $23.25 billion, a price-to-earnings ratio of 20.22, a PEG ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period in the previous year, the business earned $6.63 EPS. The firm’s revenue was down 1.6% compared to the same quarter last year. As a group, analysts predict that United Therapeutics Corporation will post 26.92 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Torren Management LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its holdings in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $31,000. International Assets Investment Management LLC raised its holdings in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 64 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB raised its holdings in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent analyst reports. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Royal Bank Of Canada dropped their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. HC Wainwright raised their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Finally, Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.